-DOCSTART- -X- O
Whereas -X- _ O
red -X- _ O
blood -X- _ O
cell -X- _ O
transfusions -X- _ O
have -X- _ O
been -X- _ O
used -X- _ O
since -X- _ O
the -X- _ O
19th -X- _ O
century -X- _ O
, -X- _ O
plasma -X- _ O
has -X- _ O
only -X- _ O
been -X- _ O
available -X- _ O
since -X- _ O
1941. -X- _ O
It -X- _ O
was -X- _ O
originally -X- _ O
mainly -X- _ O
used -X- _ O
as -X- _ O
volume -X- _ O
replacement -X- _ O
, -X- _ O
mostly -X- _ O
during -X- _ O
World -X- _ O
War -X- _ O
II -X- _ O
and -X- _ O
the -X- _ O
Korean -X- _ O
War. -X- _ O
Over -X- _ O
the -X- _ O
years -X- _ O
, -X- _ O
its -X- _ O
indication -X- _ O
has -X- _ O
shifted -X- _ O
to -X- _ O
correct -X- _ O
coagulation -X- _ O
factors -X- _ O
deficiencies -X- _ O
or -X- _ O
to -X- _ O
prevent -X- _ O
bleeding. -X- _ O
Currently -X- _ O
, -X- _ O
it -X- _ O
remains -X- _ O
a -X- _ O
frequent -X- _ O
treatment -X- _ O
in -X- _ O
the -X- _ O
intensive -X- _ O
care -X- _ O
unit -X- _ O
, -X- _ O
both -X- _ O
for -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
adults -X- _ I-Patient
and -X- _ I-Patient
children. -X- _ I-Patient
However -X- _ O
, -X- _ O
observational -X- _ B-Outcome
studies -X- _ I-Outcome
have -X- _ I-Outcome
shown -X- _ I-Outcome
that -X- _ I-Outcome
plasma -X- _ I-Outcome
transfusion -X- _ I-Outcome
fail -X- _ I-Outcome
to -X- _ I-Outcome
correct -X- _ I-Outcome
mildly -X- _ I-Outcome
abnormal -X- _ I-Outcome
coagulation -X- _ I-Outcome
tests. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
recent -X- _ O
epidemiological -X- _ O
studies -X- _ O
have -X- _ O
shown -X- _ O
that -X- _ O
plasma -X- _ B-Intervention
transfusions -X- _ I-Intervention
are -X- _ O
associated -X- _ B-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
increased -X- _ I-Outcome
morbidity -X- _ I-Outcome
and -X- _ I-Outcome
mortality -X- _ I-Outcome
in -X- _ I-Outcome
critically -X- _ I-Outcome
ill -X- _ I-Outcome
patients. -X- _ I-Outcome
Therefore -X- _ O
, -X- _ O
plasma -X- _ O
, -X- _ O
as -X- _ O
any -X- _ O
other -X- _ O
treatment -X- _ O
, -X- _ O
has -X- _ O
to -X- _ O
be -X- _ O
used -X- _ O
when -X- _ O
the -X- _ O
benefits -X- _ O
outweigh -X- _ O
the -X- _ O
risks. -X- _ O
Based -X- _ O
on -X- _ O
observational -X- _ O
data -X- _ O
, -X- _ O
most -X- _ O
experts -X- _ O
suggest -X- _ O
limiting -X- _ B-Outcome
its -X- _ I-Outcome
use -X- _ I-Outcome
either -X- _ I-Outcome
to -X- _ I-Outcome
massively -X- _ I-Outcome
bleeding -X- _ I-Outcome
patients -X- _ I-Outcome
or -X- _ I-Outcome
bleeding -X- _ I-Outcome
patients -X- _ I-Outcome
who -X- _ I-Outcome
have -X- _ I-Outcome
documented -X- _ I-Outcome
abnormal -X- _ I-Outcome
coagulation -X- _ I-Outcome
tests -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
refraining -X- _ I-Outcome
for -X- _ I-Outcome
transfusing -X- _ I-Outcome
plasma -X- _ I-Outcome
to -X- _ I-Outcome
nonbleeding -X- _ I-Outcome
patients -X- _ I-Outcome
whatever -X- _ I-Outcome
their -X- _ I-Outcome
coagulation -X- _ I-Outcome
tests. -X- _ I-Outcome
In -X- _ O
this -X- _ O
paper -X- _ O
, -X- _ O
we -X- _ O
will -X- _ O
review -X- _ O
current -X- _ O
evidence -X- _ O
on -X- _ O
plasma -X- _ B-Intervention
transfusions -X- _ I-Intervention
and -X- _ O
discuss -X- _ O
its -X- _ O
indications -X- _ O
. -X- _ O

